Please assess the completion status of the following clinical trial:

Trial Title: Nordihydroguaiaretic Acid in Treating Patients With Nonmetastatic Relapsed Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed prostate cancer, meeting 1 of the following criteria:~  * Androgen-dependent disease (testosterone ≥ 250 ng/mL)~ * Androgen-independent disease (testosterone \< 50 ng/mL)~* Received prior definitive therapy for primary prostate cancer comprising any of the following:~  * External-beam radiotherapy with or without hormonal therapy~ * Brachytherapy with or without pelvic external-beam radiotherapy or hormonal therapy~ * Radical prostatectomy with or without adjuvant or salvage radiotherapy~ * Cryotherapy~* Must have evidence of disease progression, as evidenced by elevated prostate-specific antigen (PSA) that has risen serially from post-definitive therapy nadir on 2 determinations taken ≥ 1 week apart~  * Elevated PSA, meeting 1 of the following criteria:~    * At least 1.0 ng/mL post radiotherapy or cryotherapy~   * At least 4 ng/mL post radical prostatectomy~ * Must show disease progression after discontinuation of the antiandrogen (for patients with androgen-dependent disease receiving antiandrogen as part of primary androgen ablation)~* No metastatic disease, confirmed by negative bone scan and negative CT scan or MRI of abdomen/pelvis~PATIENT CHARACTERISTICS:~* Karnofsky performance status 70-100%~* Absolute neutrophil count ≥ 1,500/mm³~* Hemoglobin ≥ 8.0 g/dL~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* AST ≤ 1.5 times ULN~* No other medical condition that would interfere with study therapy or compliance~* No other active malignancy except previously treated squamous cell or basal cell skin cancer or cancer that has been treated and considered to be at \< 30% risk of relapse~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 8 weeks since prior strontium-chloride Sr 89~* More than 4 weeks since first dose of bisphosphonates~* More than 4 weeks since prior major surgery or radiotherapy~* At least 4 weeks since prior hormonal agents, including megestrol or steroids~  * Concurrent luteinizing hormone-releasing hormone analogs allowed to maintain castrate levels of testosterone~* At least 4 weeks since prior and no concurrent saw palmetto, finasteride, or any herbal agent intended to lower PSA~* Prior adjuvant or neoadjuvant androgen-deprivation therapy allowed for androgen-dependent prostate cancer provided that all of the following are met:~  * No more than 8 months of androgen deprivation~ * At least 12 months since last day of effective androgen deprivation~ * Testosterone \> 250 ng/mL at enrollment~* Prior hormonal therapy, chemotherapy, or investigational therapy for biochemical relapse allowed~* No concurrent chemotherapeutic, immunotherapeutic, or other investigational agents~* No concurrent radiotherapy~* No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy